IFN-γ signaling activates expression of CTLA-4 in melanoma cells, and after ipilimumab (anti-CTLA-4) treatment, human melanomas upregulated IFN-γ responsive genes, including CTLA-4, which associated with durable response (29). This evidence concerns the gene IFNG and melanoma.